| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cryptococcus neoformans | 81 | 2024 | 141 | 14.080 |
Why?
|
| Cryptococcosis | 37 | 2025 | 73 | 9.010 |
Why?
|
| Fungal Vaccines | 21 | 2024 | 44 | 6.600 |
Why?
|
| Antigens, Fungal | 25 | 2025 | 55 | 4.240 |
Why?
|
| Mycoses | 18 | 2017 | 41 | 3.980 |
Why?
|
| Dendritic Cells | 22 | 2018 | 507 | 3.140 |
Why?
|
| Glucans | 11 | 2024 | 63 | 2.710 |
Why?
|
| Aspergillosis | 12 | 2023 | 34 | 2.660 |
Why?
|
| Fungi | 15 | 2022 | 51 | 2.600 |
Why?
|
| Chitosan | 8 | 2024 | 82 | 2.570 |
Why?
|
| Membrane Glycoproteins | 19 | 2018 | 660 | 2.410 |
Why?
|
| Aspergillus fumigatus | 17 | 2023 | 37 | 2.210 |
Why?
|
| Pulmonary Aspergillosis | 3 | 2023 | 9 | 2.160 |
Why?
|
| Phagocytosis | 30 | 2012 | 249 | 2.140 |
Why?
|
| Lectins, C-Type | 14 | 2018 | 77 | 2.140 |
Why?
|
| Macrophages | 23 | 2019 | 1000 | 1.860 |
Why?
|
| Receptors, Cell Surface | 15 | 2009 | 428 | 1.840 |
Why?
|
| Mice | 67 | 2024 | 10251 | 1.830 |
Why?
|
| Candida albicans | 22 | 2014 | 55 | 1.820 |
Why?
|
| Animals | 93 | 2024 | 19601 | 1.800 |
Why?
|
| Mice, Inbred C57BL | 36 | 2024 | 3220 | 1.780 |
Why?
|
| Cryptococcus | 9 | 2013 | 12 | 1.770 |
Why?
|
| Vaccines | 7 | 2024 | 95 | 1.720 |
Why?
|
| Fungal Proteins | 11 | 2019 | 144 | 1.690 |
Why?
|
| Vaccines, Subunit | 6 | 2024 | 40 | 1.630 |
Why?
|
| CD4-Positive T-Lymphocytes | 12 | 2024 | 620 | 1.580 |
Why?
|
| T-Lymphocytes | 15 | 2024 | 983 | 1.570 |
Why?
|
| AIDS-Related Opportunistic Infections | 10 | 2025 | 68 | 1.550 |
Why?
|
| Cryptococcus gattii | 4 | 2024 | 12 | 1.470 |
Why?
|
| Leukocytes, Mononuclear | 14 | 2009 | 238 | 1.440 |
Why?
|
| Immunocompromised Host | 7 | 2021 | 98 | 1.430 |
Why?
|
| Polysaccharides | 9 | 2011 | 141 | 1.390 |
Why?
|
| HIV Infections | 8 | 2025 | 912 | 1.380 |
Why?
|
| Antifungal Agents | 17 | 2020 | 115 | 1.380 |
Why?
|
| Interleukin-17 | 3 | 2021 | 88 | 1.380 |
Why?
|
| Adjuvants, Immunologic | 6 | 2024 | 224 | 1.350 |
Why?
|
| beta-Glucans | 8 | 2017 | 48 | 1.340 |
Why?
|
| Meningitis, Cryptococcal | 5 | 2025 | 14 | 1.320 |
Why?
|
| Interleukin-23 | 2 | 2021 | 19 | 1.300 |
Why?
|
| Eosinophils | 2 | 2021 | 52 | 1.280 |
Why?
|
| Hypersensitivity | 2 | 2021 | 63 | 1.250 |
Why?
|
| Host-Pathogen Interactions | 4 | 2017 | 236 | 1.250 |
Why?
|
| Liver Transplantation | 2 | 2021 | 207 | 1.210 |
Why?
|
| Immunity, Innate | 10 | 2022 | 765 | 1.200 |
Why?
|
| Saccharomyces cerevisiae | 11 | 2023 | 537 | 1.200 |
Why?
|
| Cell Wall | 10 | 2019 | 112 | 1.190 |
Why?
|
| Mannose-Binding Lectins | 10 | 2009 | 21 | 1.140 |
Why?
|
| Humans | 135 | 2025 | 59282 | 1.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 15 | 2013 | 583 | 1.070 |
Why?
|
| Interferon-gamma | 11 | 2024 | 551 | 1.050 |
Why?
|
| Vaccination | 7 | 2024 | 333 | 1.030 |
Why?
|
| Lung Diseases, Fungal | 10 | 2018 | 32 | 1.010 |
Why?
|
| Chloroquine | 7 | 2002 | 49 | 0.950 |
Why?
|
| Lipopolysaccharide Receptors | 6 | 2004 | 143 | 0.930 |
Why?
|
| Ovalbumin | 6 | 2017 | 115 | 0.910 |
Why?
|
| Cytokines | 17 | 2019 | 904 | 0.880 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2023 | 5 | 0.870 |
Why?
|
| Drug Carriers | 2 | 2017 | 175 | 0.870 |
Why?
|
| Disease Models, Animal | 12 | 2024 | 2046 | 0.850 |
Why?
|
| Lung | 11 | 2023 | 913 | 0.840 |
Why?
|
| Monocytes | 9 | 2019 | 343 | 0.820 |
Why?
|
| Recombinant Proteins | 11 | 2021 | 688 | 0.820 |
Why?
|
| Hemostatics | 2 | 2014 | 26 | 0.810 |
Why?
|
| Invasive Fungal Infections | 2 | 2019 | 6 | 0.800 |
Why?
|
| Histoplasma | 3 | 2018 | 15 | 0.780 |
Why?
|
| Toll-Like Receptor 9 | 3 | 2019 | 197 | 0.770 |
Why?
|
| Killer Cells, Natural | 7 | 2015 | 215 | 0.760 |
Why?
|
| Mucormycosis | 2 | 2021 | 9 | 0.760 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 14 | 0.760 |
Why?
|
| Receptors, Interleukin | 1 | 2021 | 39 | 0.750 |
Why?
|
| Cells, Cultured | 20 | 2018 | 2089 | 0.740 |
Why?
|
| Chitin | 6 | 2015 | 39 | 0.740 |
Why?
|
| Immunotherapy | 4 | 2017 | 230 | 0.730 |
Why?
|
| Influenza, Human | 1 | 2023 | 191 | 0.720 |
Why?
|
| Candida | 3 | 2020 | 33 | 0.700 |
Why?
|
| Coccidioides | 4 | 2013 | 10 | 0.690 |
Why?
|
| Mannose | 3 | 2007 | 21 | 0.670 |
Why?
|
| Aspergillus | 2 | 2016 | 10 | 0.670 |
Why?
|
| Mice, Knockout | 13 | 2021 | 1985 | 0.660 |
Why?
|
| Virulence | 10 | 2023 | 186 | 0.650 |
Why?
|
| Lysosomes | 4 | 2008 | 156 | 0.630 |
Why?
|
| Neutrophils | 15 | 2006 | 353 | 0.630 |
Why?
|
| Immunity, Cellular | 12 | 2018 | 169 | 0.630 |
Why?
|
| Histoplasmosis | 3 | 2018 | 23 | 0.630 |
Why?
|
| Bone Marrow Cells | 4 | 2014 | 231 | 0.620 |
Why?
|
| Toll-Like Receptors | 9 | 2009 | 425 | 0.620 |
Why?
|
| Complement C3 | 4 | 2012 | 59 | 0.610 |
Why?
|
| Candidemia | 1 | 2018 | 10 | 0.590 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2018 | 21 | 0.590 |
Why?
|
| Amidohydrolases | 4 | 2022 | 35 | 0.580 |
Why?
|
| Coccidioidomycosis | 3 | 2013 | 11 | 0.580 |
Why?
|
| Drug Users | 1 | 2018 | 28 | 0.580 |
Why?
|
| Amphotericin B | 4 | 2009 | 21 | 0.570 |
Why?
|
| Toll-Like Receptor 4 | 8 | 2009 | 338 | 0.570 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2018 | 74 | 0.560 |
Why?
|
| Phagocytes | 5 | 2002 | 49 | 0.560 |
Why?
|
| Tularemia | 3 | 2024 | 16 | 0.550 |
Why?
|
| Francisella tularensis | 3 | 2024 | 22 | 0.540 |
Why?
|
| Immunologic Factors | 1 | 2017 | 102 | 0.530 |
Why?
|
| Antigens, Differentiation | 4 | 2004 | 137 | 0.530 |
Why?
|
| Bacterial Capsules | 2 | 2006 | 18 | 0.520 |
Why?
|
| Interleukin-12 | 5 | 2007 | 123 | 0.520 |
Why?
|
| Macrolides | 3 | 2001 | 37 | 0.520 |
Why?
|
| Receptors, Immunologic | 4 | 2005 | 176 | 0.520 |
Why?
|
| Bacterial Vaccines | 3 | 2024 | 86 | 0.510 |
Why?
|
| Lymphocyte Activation | 12 | 2019 | 743 | 0.500 |
Why?
|
| Signal Transduction | 8 | 2019 | 2888 | 0.490 |
Why?
|
| Complement Activation | 3 | 2011 | 49 | 0.490 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 2019 | 242 | 0.490 |
Why?
|
| Drug Delivery Systems | 3 | 2019 | 311 | 0.490 |
Why?
|
| Inflammasomes | 3 | 2018 | 324 | 0.480 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2024 | 648 | 0.480 |
Why?
|
| Myeloid Differentiation Factor 88 | 4 | 2011 | 202 | 0.480 |
Why?
|
| Opportunistic Infections | 5 | 2019 | 29 | 0.470 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2025 | 90 | 0.460 |
Why?
|
| Extracellular Traps | 1 | 2015 | 40 | 0.460 |
Why?
|
| Immunity, Active | 1 | 2013 | 10 | 0.450 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2013 | 1 | 0.440 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 2017 | 137 | 0.440 |
Why?
|
| Immune Tolerance | 2 | 2013 | 172 | 0.430 |
Why?
|
| Receptors, Interleukin-1 | 2 | 2011 | 66 | 0.430 |
Why?
|
| Plant Immunity | 1 | 2013 | 2 | 0.420 |
Why?
|
| Interleukin-1beta | 4 | 2018 | 256 | 0.420 |
Why?
|
| Interleukin-2 | 7 | 1997 | 164 | 0.410 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2013 | 32 | 0.400 |
Why?
|
| HIV Seropositivity | 5 | 2001 | 82 | 0.400 |
Why?
|
| Th1 Cells | 4 | 2018 | 174 | 0.400 |
Why?
|
| Asthma | 1 | 2017 | 452 | 0.400 |
Why?
|
| Mice, Inbred BALB C | 9 | 2019 | 868 | 0.400 |
Why?
|
| Drosophila Proteins | 3 | 2002 | 679 | 0.400 |
Why?
|
| Complement Pathway, Alternative | 2 | 2011 | 22 | 0.390 |
Why?
|
| Toll-Like Receptor 2 | 8 | 2009 | 217 | 0.390 |
Why?
|
| Receptors, Interleukin-18 | 1 | 2011 | 10 | 0.380 |
Why?
|
| Properdin | 1 | 2011 | 13 | 0.380 |
Why?
|
| HIV | 3 | 2013 | 68 | 0.370 |
Why?
|
| Congresses as Topic | 1 | 2011 | 73 | 0.370 |
Why?
|
| Lymphocytes | 3 | 1997 | 190 | 0.370 |
Why?
|
| Mannans | 5 | 2014 | 19 | 0.360 |
Why?
|
| Microscopy, Confocal | 4 | 2017 | 220 | 0.360 |
Why?
|
| Lipopolysaccharides | 5 | 2002 | 626 | 0.350 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 365 | 0.350 |
Why?
|
| Male | 22 | 2025 | 27727 | 0.350 |
Why?
|
| Immunity, Humoral | 1 | 2010 | 37 | 0.350 |
Why?
|
| DNA, Fungal | 2 | 2008 | 57 | 0.340 |
Why?
|
| Virulence Factors | 4 | 2023 | 80 | 0.340 |
Why?
|
| Gene Expression Regulation | 7 | 2015 | 1547 | 0.330 |
Why?
|
| Candidiasis | 6 | 2014 | 39 | 0.330 |
Why?
|
| Female | 24 | 2025 | 30695 | 0.320 |
Why?
|
| Interleukin-10 | 4 | 2018 | 149 | 0.320 |
Why?
|
| Blastomyces | 2 | 2021 | 3 | 0.320 |
Why?
|
| Endosomes | 2 | 2008 | 169 | 0.320 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2009 | 109 | 0.320 |
Why?
|
| Opsonin Proteins | 8 | 2008 | 31 | 0.320 |
Why?
|
| Cell Line | 8 | 2011 | 1968 | 0.320 |
Why?
|
| Flow Cytometry | 6 | 2019 | 639 | 0.310 |
Why?
|
| Interleukin-1 | 4 | 2003 | 156 | 0.300 |
Why?
|
| Receptors, Mitogen | 2 | 2006 | 6 | 0.300 |
Why?
|
| Glycoproteins | 2 | 2006 | 186 | 0.290 |
Why?
|
| Ascomycota | 2 | 2021 | 11 | 0.290 |
Why?
|
| Antigen Presentation | 2 | 2007 | 223 | 0.290 |
Why?
|
| Antibodies, Fungal | 6 | 2008 | 11 | 0.280 |
Why?
|
| Leukocytes | 3 | 1999 | 97 | 0.280 |
Why?
|
| Vaccines, Synthetic | 3 | 2017 | 67 | 0.280 |
Why?
|
| Paracoccidioides | 2 | 2018 | 37 | 0.280 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 732 | 0.280 |
Why?
|
| Hyphae | 3 | 2015 | 14 | 0.270 |
Why?
|
| CpG Islands | 1 | 2008 | 211 | 0.270 |
Why?
|
| Th17 Cells | 2 | 2018 | 57 | 0.270 |
Why?
|
| Chemokine CCL2 | 2 | 1997 | 54 | 0.270 |
Why?
|
| Rats, Inbred F344 | 2 | 2024 | 52 | 0.270 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2019 | 15 | 0.270 |
Why?
|
| Macrophages, Alveolar | 5 | 2006 | 59 | 0.260 |
Why?
|
| Comorbidity | 2 | 2021 | 1078 | 0.260 |
Why?
|
| Inflammation | 3 | 2023 | 1094 | 0.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 328 | 0.250 |
Why?
|
| Caspase 8 | 2 | 2018 | 61 | 0.250 |
Why?
|
| Coinfection | 2 | 2024 | 44 | 0.250 |
Why?
|
| NF-kappa B | 7 | 2019 | 458 | 0.250 |
Why?
|
| Receptors, Complement | 3 | 1997 | 17 | 0.250 |
Why?
|
| Cell Survival | 5 | 2011 | 559 | 0.250 |
Why?
|
| Carrier Proteins | 4 | 2014 | 696 | 0.250 |
Why?
|
| Adult | 15 | 2025 | 15663 | 0.250 |
Why?
|
| Enzyme Inhibitors | 3 | 2002 | 349 | 0.250 |
Why?
|
| Liberia | 1 | 2025 | 9 | 0.240 |
Why?
|
| Zymosan | 5 | 2011 | 24 | 0.230 |
Why?
|
| Cell Nucleus | 4 | 2019 | 606 | 0.230 |
Why?
|
| Cloning, Molecular | 3 | 2017 | 381 | 0.230 |
Why?
|
| Molecular Sequence Data | 10 | 2012 | 1949 | 0.230 |
Why?
|
| Treatment Outcome | 4 | 2017 | 5283 | 0.230 |
Why?
|
| Biological Evolution | 2 | 2023 | 114 | 0.220 |
Why?
|
| Hybridomas | 4 | 2008 | 64 | 0.220 |
Why?
|
| Middle Aged | 9 | 2025 | 16310 | 0.220 |
Why?
|
| Hydrogen-Ion Concentration | 8 | 2004 | 447 | 0.220 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2020 | 189 | 0.220 |
Why?
|
| MAP Kinase Signaling System | 2 | 2002 | 202 | 0.220 |
Why?
|
| Vaccines, Attenuated | 3 | 2024 | 33 | 0.210 |
Why?
|
| Young Adult | 3 | 2025 | 4266 | 0.210 |
Why?
|
| Bacteria | 2 | 1996 | 279 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 4 | 2021 | 730 | 0.210 |
Why?
|
| Pichia | 3 | 2007 | 4 | 0.210 |
Why?
|
| Phylogeny | 3 | 2021 | 336 | 0.200 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 3 | 2014 | 250 | 0.200 |
Why?
|
| Gene Expression | 4 | 2017 | 808 | 0.200 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2013 | 244 | 0.200 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2002 | 1 | 0.200 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2012 | 176 | 0.200 |
Why?
|
| Phagosomes | 2 | 2000 | 43 | 0.200 |
Why?
|
| Vacuoles | 1 | 2002 | 26 | 0.200 |
Why?
|
| Glycoconjugates | 1 | 2002 | 2 | 0.200 |
Why?
|
| Amoeba | 1 | 2001 | 1 | 0.190 |
Why?
|
| CHO Cells | 4 | 2007 | 189 | 0.190 |
Why?
|
| Immunization, Passive | 2 | 2016 | 99 | 0.190 |
Why?
|
| Peptides | 3 | 2021 | 547 | 0.190 |
Why?
|
| CD18 Antigens | 1 | 2002 | 30 | 0.190 |
Why?
|
| Complement System Proteins | 3 | 2008 | 114 | 0.190 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2015 | 105 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2015 | 445 | 0.190 |
Why?
|
| Cricetinae | 4 | 2007 | 365 | 0.190 |
Why?
|
| Mycology | 3 | 2021 | 7 | 0.190 |
Why?
|
| Prescription Drug Overuse | 1 | 2021 | 7 | 0.190 |
Why?
|
| Military Personnel | 1 | 2022 | 97 | 0.190 |
Why?
|
| In Vitro Techniques | 9 | 1996 | 469 | 0.190 |
Why?
|
| Scedosporium | 1 | 2021 | 1 | 0.180 |
Why?
|
| Escherichia coli | 3 | 2017 | 693 | 0.180 |
Why?
|
| Adaptive Immunity | 2 | 2022 | 96 | 0.180 |
Why?
|
| Fusarium | 1 | 2021 | 5 | 0.180 |
Why?
|
| Tacrolimus | 1 | 2021 | 62 | 0.180 |
Why?
|
| Respiratory Burst | 4 | 2005 | 19 | 0.180 |
Why?
|
| Risk Factors | 3 | 2021 | 4982 | 0.180 |
Why?
|
| Mycophenolic Acid | 1 | 2021 | 67 | 0.180 |
Why?
|
| HIV Seronegativity | 5 | 2000 | 18 | 0.180 |
Why?
|
| India | 1 | 2021 | 150 | 0.180 |
Why?
|
| Diabetes Complications | 1 | 2021 | 100 | 0.180 |
Why?
|
| Quinacrine | 1 | 2000 | 3 | 0.180 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.180 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2021 | 69 | 0.180 |
Why?
|
| Anti-HIV Agents | 2 | 2019 | 153 | 0.170 |
Why?
|
| Chemokines, CC | 1 | 2000 | 30 | 0.170 |
Why?
|
| Dexamethasone | 1 | 2021 | 201 | 0.170 |
Why?
|
| Interleukin-15 | 1 | 2000 | 24 | 0.170 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 101 | 0.170 |
Why?
|
| Penicillium | 1 | 1999 | 1 | 0.170 |
Why?
|
| Kangai-1 Protein | 1 | 2019 | 3 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2021 | 179 | 0.160 |
Why?
|
| Viral Load | 2 | 2013 | 219 | 0.160 |
Why?
|
| Antigens | 3 | 2023 | 146 | 0.160 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2019 | 16 | 0.160 |
Why?
|
| Interleukin-7 | 1 | 2019 | 30 | 0.160 |
Why?
|
| Interleukin-8 | 2 | 1996 | 86 | 0.160 |
Why?
|
| Cell Separation | 2 | 2017 | 145 | 0.160 |
Why?
|
| Biomedical Research | 2 | 2012 | 249 | 0.160 |
Why?
|
| Ligands | 2 | 2012 | 410 | 0.160 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 291 | 0.160 |
Why?
|
| Th2 Cells | 2 | 2018 | 99 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2006 | 806 | 0.150 |
Why?
|
| Paracoccidioidomycosis | 1 | 2018 | 25 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 52 | 0.140 |
Why?
|
| Caspase 1 | 1 | 2018 | 107 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 157 | 0.140 |
Why?
|
| K562 Cells | 2 | 2007 | 57 | 0.140 |
Why?
|
| Sporothrix | 1 | 1996 | 3 | 0.140 |
Why?
|
| Mucor | 1 | 1996 | 3 | 0.140 |
Why?
|
| Mouth | 1 | 1996 | 33 | 0.130 |
Why?
|
| Immune System | 1 | 2017 | 129 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2020 | 423 | 0.130 |
Why?
|
| Critical Care | 1 | 2020 | 397 | 0.130 |
Why?
|
| Survival Analysis | 1 | 2017 | 555 | 0.130 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2016 | 89 | 0.130 |
Why?
|
| Active Transport, Cell Nucleus | 3 | 2019 | 107 | 0.130 |
Why?
|
| HIV-1 | 2 | 2000 | 692 | 0.130 |
Why?
|
| Injections, Subcutaneous | 1 | 2015 | 69 | 0.130 |
Why?
|
| Chromatography, Gel | 1 | 2015 | 65 | 0.130 |
Why?
|
| Base Sequence | 4 | 2010 | 1300 | 0.130 |
Why?
|
| Chromatography, Liquid | 1 | 2015 | 126 | 0.120 |
Why?
|
| Eukaryota | 1 | 1995 | 29 | 0.120 |
Why?
|
| Hexosaminidases | 1 | 2015 | 6 | 0.120 |
Why?
|
| Cell Degranulation | 2 | 1997 | 20 | 0.120 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 141 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1993 | 73 | 0.120 |
Why?
|
| Vaccines, Conjugate | 1 | 2014 | 17 | 0.120 |
Why?
|
| Vaccines, Inactivated | 1 | 2014 | 12 | 0.120 |
Why?
|
| Fungal Polysaccharides | 1 | 2014 | 4 | 0.120 |
Why?
|
| Carbohydrates | 1 | 2014 | 38 | 0.120 |
Why?
|
| Macrophage-1 Antigen | 1 | 2014 | 30 | 0.120 |
Why?
|
| Immunoconjugates | 1 | 2014 | 85 | 0.110 |
Why?
|
| Mice, Mutant Strains | 2 | 2005 | 297 | 0.110 |
Why?
|
| Transfection | 3 | 2002 | 675 | 0.110 |
Why?
|
| Vaccines, Live, Unattenuated | 1 | 2013 | 2 | 0.110 |
Why?
|
| Peyer's Patches | 1 | 2014 | 35 | 0.110 |
Why?
|
| RNA, Messenger | 6 | 2000 | 1464 | 0.110 |
Why?
|
| Amino Acid Sequence | 6 | 2010 | 1552 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 294 | 0.110 |
Why?
|
| Rats | 3 | 2024 | 1909 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 6 | 2010 | 837 | 0.110 |
Why?
|
| Mice, Inbred C3H | 2 | 2004 | 173 | 0.110 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 441 | 0.110 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 201 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 3 | 2002 | 450 | 0.100 |
Why?
|
| Lymphopenia | 1 | 1993 | 35 | 0.100 |
Why?
|
| Species Specificity | 3 | 2019 | 328 | 0.100 |
Why?
|
| Oxygen Consumption | 4 | 1989 | 206 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2004 | 411 | 0.100 |
Why?
|
| Bursitis | 1 | 2012 | 13 | 0.100 |
Why?
|
| Hydrogen Peroxide | 5 | 1997 | 76 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2018 | 1298 | 0.100 |
Why?
|
| Empiricism | 1 | 2012 | 3 | 0.100 |
Why?
|
| Endothelium, Vascular | 1 | 1993 | 169 | 0.100 |
Why?
|
| Antibodies, Blocking | 1 | 2012 | 40 | 0.100 |
Why?
|
| Immunoglobulin G | 2 | 2013 | 445 | 0.100 |
Why?
|
| Knee Injuries | 1 | 2012 | 47 | 0.100 |
Why?
|
| Eye Infections, Fungal | 1 | 1992 | 2 | 0.100 |
Why?
|
| Massachusetts | 1 | 2018 | 2003 | 0.100 |
Why?
|
| Kinetics | 4 | 1997 | 750 | 0.100 |
Why?
|
| Fungemia | 1 | 1992 | 6 | 0.100 |
Why?
|
| Financing, Government | 1 | 2012 | 30 | 0.100 |
Why?
|
| Endophthalmitis | 1 | 1992 | 11 | 0.100 |
Why?
|
| Research Support as Topic | 1 | 2012 | 39 | 0.100 |
Why?
|
| Communicable Disease Control | 1 | 2012 | 36 | 0.100 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2011 | 12 | 0.100 |
Why?
|
| Tetrazolium Salts | 2 | 1995 | 15 | 0.100 |
Why?
|
| Cytochalasin D | 1 | 2011 | 18 | 0.100 |
Why?
|
| Natural Killer T-Cells | 1 | 2011 | 27 | 0.090 |
Why?
|
| Marijuana Smoking | 1 | 1991 | 16 | 0.090 |
Why?
|
| Gliotoxin | 1 | 2011 | 4 | 0.090 |
Why?
|
| Transcription, Genetic | 3 | 2001 | 844 | 0.090 |
Why?
|
| Kidney Transplantation | 2 | 2012 | 312 | 0.090 |
Why?
|
| Communicable Diseases | 1 | 2012 | 84 | 0.090 |
Why?
|
| Phenotype | 2 | 2013 | 1136 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2018 | 1920 | 0.090 |
Why?
|
| Particle Size | 1 | 2013 | 395 | 0.090 |
Why?
|
| Glycosylation | 2 | 2010 | 129 | 0.090 |
Why?
|
| Hot Temperature | 3 | 2016 | 126 | 0.090 |
Why?
|
| History, 21st Century | 1 | 2011 | 162 | 0.090 |
Why?
|
| B-Lymphocytes | 3 | 2004 | 549 | 0.090 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 1990 | 2 | 0.090 |
Why?
|
| Mitosporic Fungi | 1 | 1990 | 2 | 0.090 |
Why?
|
| Polysaccharides, Bacterial | 1 | 2010 | 43 | 0.090 |
Why?
|
| History, 20th Century | 1 | 2011 | 223 | 0.090 |
Why?
|
| Structure-Activity Relationship | 1 | 2011 | 363 | 0.090 |
Why?
|
| Chemokine CCL5 | 2 | 2000 | 32 | 0.090 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 1992 | 101 | 0.080 |
Why?
|
| Ammonium Chloride | 2 | 2001 | 10 | 0.080 |
Why?
|
| Rhizopus | 2 | 1986 | 5 | 0.080 |
Why?
|
| Cell Division | 3 | 2000 | 443 | 0.080 |
Why?
|
| Actins | 1 | 1991 | 258 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 2 | 2000 | 43 | 0.080 |
Why?
|
| Carbohydrate Sequence | 1 | 2009 | 22 | 0.080 |
Why?
|
| Blood Donors | 2 | 2000 | 22 | 0.080 |
Why?
|
| Peritoneal Cavity | 1 | 1988 | 31 | 0.080 |
Why?
|
| Neutropenia | 1 | 2009 | 62 | 0.080 |
Why?
|
| DNA Primers | 2 | 2001 | 289 | 0.080 |
Why?
|
| Microscopy, Video | 1 | 2008 | 37 | 0.080 |
Why?
|
| Factitious Disorders | 1 | 1988 | 2 | 0.080 |
Why?
|
| Microbial Viability | 1 | 2008 | 55 | 0.080 |
Why?
|
| DNA-Cytosine Methylases | 1 | 2008 | 3 | 0.080 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2008 | 43 | 0.070 |
Why?
|
| Cell Compartmentation | 1 | 2008 | 34 | 0.070 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 1995 | 145 | 0.070 |
Why?
|
| Intracellular Space | 1 | 2008 | 33 | 0.070 |
Why?
|
| Cell Adhesion | 3 | 1996 | 207 | 0.070 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2002 | 67 | 0.070 |
Why?
|
| Herpes Zoster | 1 | 1988 | 23 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2008 | 132 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2009 | 305 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2009 | 365 | 0.070 |
Why?
|
| Chemokines | 1 | 2008 | 92 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2009 | 673 | 0.070 |
Why?
|
| Endonucleases | 1 | 2008 | 80 | 0.070 |
Why?
|
| Cricetulus | 1 | 2007 | 99 | 0.070 |
Why?
|
| Thiazoles | 2 | 1995 | 46 | 0.070 |
Why?
|
| Cell Adhesion Molecules | 1 | 2007 | 85 | 0.070 |
Why?
|
| Skin Diseases | 1 | 1988 | 76 | 0.070 |
Why?
|
| Prognosis | 1 | 2011 | 1599 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 168 | 0.070 |
Why?
|
| Fluoresceins | 2 | 2002 | 29 | 0.070 |
Why?
|
| Minority Groups | 1 | 1988 | 135 | 0.070 |
Why?
|
| Binding Sites | 2 | 2001 | 881 | 0.070 |
Why?
|
| Birds | 2 | 2000 | 8 | 0.070 |
Why?
|
| Molecular Weight | 2 | 2001 | 184 | 0.070 |
Why?
|
| Genes, Fungal | 2 | 2005 | 56 | 0.070 |
Why?
|
| Glycosylphosphatidylinositols | 1 | 2006 | 24 | 0.070 |
Why?
|
| Blood Proteins | 1 | 1986 | 75 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 416 | 0.070 |
Why?
|
| CD11c Antigen | 1 | 2006 | 8 | 0.060 |
Why?
|
| Antibody Formation | 1 | 2006 | 108 | 0.060 |
Why?
|
| Time Factors | 3 | 2008 | 3614 | 0.060 |
Why?
|
| Chitin Synthase | 1 | 2005 | 12 | 0.060 |
Why?
|
| Periodicals as Topic | 1 | 1988 | 166 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 1987 | 196 | 0.060 |
Why?
|
| Zygomycosis | 1 | 2005 | 1 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2006 | 940 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 248 | 0.060 |
Why?
|
| Immunophenotyping | 2 | 2015 | 184 | 0.060 |
Why?
|
| Blood Bactericidal Activity | 2 | 2000 | 66 | 0.060 |
Why?
|
| Fluorescein-5-isothiocyanate | 2 | 1999 | 20 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2005 | 583 | 0.060 |
Why?
|
| Spleen | 1 | 2005 | 480 | 0.060 |
Why?
|
| Glucuronidase | 2 | 1997 | 23 | 0.060 |
Why?
|
| Calcium | 1 | 1987 | 554 | 0.060 |
Why?
|
| Mutation | 4 | 2016 | 2452 | 0.060 |
Why?
|
| Models, Biological | 1 | 2009 | 1140 | 0.060 |
Why?
|
| Rosette Formation | 2 | 1994 | 12 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2004 | 182 | 0.050 |
Why?
|
| South Africa | 2 | 2013 | 10 | 0.050 |
Why?
|
| Gene Expression Regulation, Fungal | 2 | 2019 | 125 | 0.050 |
Why?
|
| Immune Evasion | 1 | 2024 | 55 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2009 | 846 | 0.050 |
Why?
|
| Antigens, Bacterial | 1 | 2024 | 200 | 0.050 |
Why?
|
| Video Recording | 2 | 1994 | 126 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2019 | 292 | 0.050 |
Why?
|
| Silicon Dioxide | 1 | 2023 | 60 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2015 | 2372 | 0.050 |
Why?
|
| Biomarkers | 1 | 2008 | 1305 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 7 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2000 | 43 | 0.050 |
Why?
|
| Immune Sera | 1 | 2002 | 34 | 0.050 |
Why?
|
| Carbohydrate Conformation | 1 | 2002 | 15 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 495 | 0.050 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2002 | 24 | 0.050 |
Why?
|
| Mannose-Binding Lectin | 1 | 2002 | 3 | 0.050 |
Why?
|
| Fluorescence | 1 | 2002 | 83 | 0.050 |
Why?
|
| fas Receptor | 1 | 2002 | 55 | 0.050 |
Why?
|
| Heterozygote | 1 | 2002 | 161 | 0.050 |
Why?
|
| Cell Line, Tumor | 1 | 2006 | 1368 | 0.050 |
Why?
|
| Flavonoids | 1 | 2002 | 73 | 0.050 |
Why?
|
| Staining and Labeling | 2 | 2017 | 123 | 0.050 |
Why?
|
| Enzyme Activation | 1 | 2002 | 358 | 0.050 |
Why?
|
| Mammals | 1 | 2023 | 208 | 0.050 |
Why?
|
| Cellulase | 1 | 2021 | 5 | 0.050 |
Why?
|
| Liver | 1 | 2005 | 796 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 32 | 0.050 |
Why?
|
| Drug Resistance, Fungal | 1 | 2021 | 10 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2002 | 179 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2002 | 205 | 0.050 |
Why?
|
| Leukocyte L1 Antigen Complex | 1 | 2000 | 5 | 0.040 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2000 | 13 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2001 | 356 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2002 | 523 | 0.040 |
Why?
|
| Iron | 2 | 2000 | 136 | 0.040 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2000 | 51 | 0.040 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2000 | 23 | 0.040 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 178 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2010 | 216 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2004 | 425 | 0.040 |
Why?
|
| Adolescent | 3 | 2019 | 5822 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2000 | 50 | 0.040 |
Why?
|
| Chemokine CCL3 | 1 | 2000 | 9 | 0.040 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2000 | 11 | 0.040 |
Why?
|
| Chemokine CCL4 | 1 | 2000 | 14 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2000 | 225 | 0.040 |
Why?
|
| Receptors, HIV | 1 | 2000 | 15 | 0.040 |
Why?
|
| Zoonoses | 1 | 2000 | 7 | 0.040 |
Why?
|
| Animals, Domestic | 1 | 2000 | 13 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2000 | 146 | 0.040 |
Why?
|
| Ribonucleases | 1 | 2000 | 31 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2021 | 89 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 2019 | 83 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2000 | 56 | 0.040 |
Why?
|
| Aged | 6 | 2000 | 13412 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2002 | 882 | 0.040 |
Why?
|
| Biological Transport | 1 | 2000 | 288 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 48 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2002 | 650 | 0.040 |
Why?
|
| Ataxia Telangiectasia | 1 | 1999 | 12 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 1999 | 27 | 0.040 |
Why?
|
| src Homology Domains | 1 | 1998 | 20 | 0.040 |
Why?
|
| Calibration | 1 | 1999 | 67 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2000 | 308 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2000 | 256 | 0.040 |
Why?
|
| Hodgkin Disease | 1 | 1999 | 55 | 0.040 |
Why?
|
| X Chromosome | 1 | 1998 | 44 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2018 | 95 | 0.040 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1998 | 38 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2002 | 1204 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2018 | 32 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2019 | 166 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1998 | 28 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2000 | 297 | 0.040 |
Why?
|
| Protein Binding | 1 | 2002 | 1554 | 0.040 |
Why?
|
| Apoproteins | 1 | 1997 | 18 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 1997 | 28 | 0.040 |
Why?
|
| HIV Reverse Transcriptase | 1 | 1997 | 10 | 0.040 |
Why?
|
| HIV Long Terminal Repeat | 1 | 1997 | 12 | 0.040 |
Why?
|
| CD4 Antigens | 2 | 1995 | 148 | 0.040 |
Why?
|
| Spores, Fungal | 3 | 1985 | 15 | 0.030 |
Why?
|
| DNA-Binding Proteins | 2 | 2000 | 1151 | 0.030 |
Why?
|
| Transferrin | 1 | 1997 | 67 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1997 | 145 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 1998 | 105 | 0.030 |
Why?
|
| Aggregatibacter actinomycetemcomitans | 1 | 1996 | 4 | 0.030 |
Why?
|
| Streptococcus mutans | 1 | 1996 | 4 | 0.030 |
Why?
|
| Porphyromonas gingivalis | 1 | 1996 | 16 | 0.030 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 2 | 1989 | 9 | 0.030 |
Why?
|
| Hydrodynamics | 1 | 2017 | 33 | 0.030 |
Why?
|
| Toxins, Biological | 1 | 1996 | 6 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1032 | 0.030 |
Why?
|
| Temperature | 2 | 2004 | 295 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1998 | 452 | 0.030 |
Why?
|
| Virion | 1 | 1997 | 119 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2018 | 146 | 0.030 |
Why?
|
| Virus Replication | 1 | 1998 | 304 | 0.030 |
Why?
|
| Immunization | 1 | 1997 | 127 | 0.030 |
Why?
|
| Mice, SCID | 1 | 1997 | 512 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 1996 | 99 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2019 | 1051 | 0.030 |
Why?
|
| Microbiological Techniques | 1 | 1995 | 5 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1995 | 29 | 0.030 |
Why?
|
| Free Radical Scavengers | 1 | 1995 | 18 | 0.030 |
Why?
|
| Spores | 2 | 1986 | 2 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1995 | 65 | 0.030 |
Why?
|
| Dinoprostone | 1 | 1995 | 44 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2000 | 390 | 0.030 |
Why?
|
| Autopsy | 1 | 2015 | 53 | 0.030 |
Why?
|
| Models, Immunological | 1 | 1995 | 84 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2013 | 3065 | 0.030 |
Why?
|
| Survival Rate | 1 | 1997 | 802 | 0.030 |
Why?
|
| Water | 1 | 2017 | 300 | 0.030 |
Why?
|
| Peroxidase | 2 | 1985 | 70 | 0.030 |
Why?
|
| Proteins | 2 | 1991 | 730 | 0.030 |
Why?
|
| Suppressor Factors, Immunologic | 1 | 1994 | 1 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2019 | 6071 | 0.030 |
Why?
|
| Polyglycolic Acid | 1 | 2014 | 16 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 1994 | 36 | 0.030 |
Why?
|
| Adhesiveness | 1 | 1993 | 13 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2014 | 71 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2015 | 390 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 1993 | 53 | 0.030 |
Why?
|
| CD56 Antigen | 1 | 1993 | 15 | 0.030 |
Why?
|
| Retroviridae Infections | 1 | 1993 | 12 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 56 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2000 | 5128 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1993 | 105 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1993 | 18 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 1993 | 107 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 93 | 0.030 |
Why?
|
| United States | 2 | 2021 | 7385 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1994 | 191 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1993 | 97 | 0.030 |
Why?
|
| Prevalence | 2 | 2000 | 1252 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2013 | 73 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 271 | 0.030 |
Why?
|
| Retroviridae | 1 | 1993 | 69 | 0.030 |
Why?
|
| Sheep | 1 | 1993 | 169 | 0.030 |
Why?
|
| Microscopy | 1 | 1993 | 88 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2012 | 179 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 187 | 0.020 |
Why?
|
| Bacterial Adhesion | 1 | 1992 | 58 | 0.020 |
Why?
|
| Erythrocytes | 1 | 1993 | 146 | 0.020 |
Why?
|
| Disease Vectors | 1 | 1991 | 7 | 0.020 |
Why?
|
| Antigens, CD1d | 1 | 2011 | 28 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1992 | 71 | 0.020 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1992 | 130 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1993 | 341 | 0.020 |
Why?
|
| Salivary Proteins and Peptides | 1 | 1991 | 5 | 0.020 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1993 | 108 | 0.020 |
Why?
|
| Dronabinol | 1 | 1991 | 31 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 674 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2012 | 259 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1991 | 22 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 1118 | 0.020 |
Why?
|
| Pancreatic Elastase | 1 | 1991 | 32 | 0.020 |
Why?
|
| Trypsin | 1 | 1991 | 39 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2011 | 176 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 902 | 0.020 |
Why?
|
| Acrolein | 1 | 1990 | 3 | 0.020 |
Why?
|
| Oxidation-Reduction | 2 | 1995 | 302 | 0.020 |
Why?
|
| Polyamines | 1 | 1990 | 11 | 0.020 |
Why?
|
| Global Health | 1 | 1991 | 167 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 459 | 0.020 |
Why?
|
| Biological Factors | 1 | 1990 | 21 | 0.020 |
Why?
|
| Fibronectins | 1 | 1990 | 43 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1990 | 31 | 0.020 |
Why?
|
| Laminin | 1 | 1990 | 74 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 288 | 0.020 |
Why?
|
| Peptides, Cyclic | 1 | 1989 | 20 | 0.020 |
Why?
|
| Lactoferrin | 1 | 1990 | 36 | 0.020 |
Why?
|
| Complement Pathway, Classical | 1 | 1989 | 20 | 0.020 |
Why?
|
| Complement C3b | 1 | 1989 | 18 | 0.020 |
Why?
|
| Chelating Agents | 1 | 1989 | 46 | 0.020 |
Why?
|
| Polylysine | 1 | 1990 | 49 | 0.020 |
Why?
|
| Collagen | 1 | 1990 | 115 | 0.020 |
Why?
|
| Pulmonary Alveoli | 2 | 1986 | 44 | 0.020 |
Why?
|
| Surface Properties | 1 | 1990 | 270 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 1990 | 132 | 0.020 |
Why?
|
| Receptors, Complement 3b | 1 | 1989 | 12 | 0.020 |
Why?
|
| Administration, Intranasal | 1 | 1989 | 28 | 0.020 |
Why?
|
| Bronchi | 2 | 1986 | 82 | 0.020 |
Why?
|
| Skin | 1 | 1992 | 357 | 0.020 |
Why?
|
| Nitrites | 1 | 1988 | 8 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1988 | 51 | 0.020 |
Why?
|
| Parotid Gland | 1 | 1988 | 11 | 0.020 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 1988 | 6 | 0.020 |
Why?
|
| Facial Dermatoses | 1 | 1988 | 10 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2000 | 527 | 0.020 |
Why?
|
| Fura-2 | 1 | 1987 | 8 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2014 | 493 | 0.020 |
Why?
|
| Benzofurans | 1 | 1987 | 10 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 1479 | 0.020 |
Why?
|
| Methods | 1 | 1987 | 41 | 0.020 |
Why?
|
| Thiocyanates | 1 | 1987 | 7 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2337 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 1487 | 0.020 |
Why?
|
| Cytosol | 1 | 1987 | 170 | 0.020 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 1986 | 51 | 0.020 |
Why?
|
| Recurrence | 1 | 1988 | 602 | 0.020 |
Why?
|
| Cell Shape | 1 | 2005 | 12 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 1985 | 35 | 0.020 |
Why?
|
| Melanins | 1 | 2005 | 21 | 0.020 |
Why?
|
| Rabbits | 1 | 1986 | 322 | 0.020 |
Why?
|
| Rose Bengal | 1 | 1985 | 7 | 0.020 |
Why?
|
| Hypochlorous Acid | 1 | 1985 | 3 | 0.020 |
Why?
|
| Superoxides | 1 | 1985 | 69 | 0.020 |
Why?
|
| Neoplasms | 1 | 1995 | 1240 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 1988 | 933 | 0.020 |
Why?
|
| Membrane Fusion | 1 | 1985 | 65 | 0.010 |
Why?
|
| Glucosyltransferases | 1 | 2004 | 13 | 0.010 |
Why?
|
| Genetic Complementation Test | 1 | 2004 | 62 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1987 | 484 | 0.010 |
Why?
|
| Homozygote | 1 | 2004 | 114 | 0.010 |
Why?
|
| Oligosaccharides | 1 | 2004 | 58 | 0.010 |
Why?
|
| Iodides | 1 | 1984 | 4 | 0.010 |
Why?
|
| Ferrous Compounds | 1 | 1984 | 12 | 0.010 |
Why?
|
| Alveolitis, Extrinsic Allergic | 1 | 1984 | 15 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1987 | 653 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2004 | 255 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 2059 | 0.010 |
Why?
|
| Xylose | 1 | 2003 | 5 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1983 | 26 | 0.010 |
Why?
|
| Alleles | 1 | 2004 | 410 | 0.010 |
Why?
|
| Acetylation | 1 | 2003 | 112 | 0.010 |
Why?
|
| Dogs | 1 | 1984 | 314 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2004 | 384 | 0.010 |
Why?
|
| Complement Factor H | 1 | 2003 | 129 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 1093 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 2000 | 14 | 0.010 |
Why?
|
| Serotyping | 1 | 2000 | 50 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2000 | 42 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 2000 | 112 | 0.010 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1999 | 37 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 1998 | 93 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1998 | 116 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 194 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 1999 | 355 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 284 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 384 | 0.010 |
Why?
|
| Biological Assay | 1 | 1991 | 55 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1995 | 1561 | 0.010 |
Why?
|
| Echinocandins | 1 | 1989 | 3 | 0.010 |
Why?
|
| Cortisone | 1 | 1984 | 1 | 0.000 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1984 | 190 | 0.000 |
Why?
|
| Tuberculin | 1 | 1983 | 1 | 0.000 |
Why?
|
| Pokeweed Mitogens | 1 | 1983 | 3 | 0.000 |
Why?
|
| Phytohemagglutinins | 1 | 1983 | 15 | 0.000 |
Why?
|
| Cyclosporins | 1 | 1983 | 17 | 0.000 |
Why?
|
| Tetanus Toxoid | 1 | 1983 | 14 | 0.000 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1983 | 33 | 0.000 |
Why?
|
| Concanavalin A | 1 | 1983 | 40 | 0.000 |
Why?
|
| Interferons | 1 | 1983 | 61 | 0.000 |
Why?
|